Our results firstly reported 3y-DFS of 94% in CRC after adjuvant anti-PD1 antibody (81.8% treated without chemotherapy) with a relatively long follow-up (median 35.5 months), much higher than historical data (3-DFS 75–80% for stage III CRC [17]). This evidence concerns the gene PDCD1 and colorectal carcinoma.